-
Lexicon Pharma's Pain Candidate Fails In Postherpetic Neuralgia Study
Thursday, December 22, 2022 - 10:22am | 312Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced the topline results of RELIEF-PHN-1 Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia, a lasting pain in the areas of the skin that had shingles. LX9211 achieved a reduction in average daily pain score (ADPS) of 2.42 from...
-
Micron, Lexicon Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Thursday, December 22, 2022 - 8:46am | 386U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. Westrock Coffee Company, LLC (NASDAQ: WEST) shares tumbled 10.9% to $11.90 in pre-market trading after gaining 10% on Wednesday. Lexicon Pharmaceuticals, Inc. (...
-
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Monday, December 19, 2022 - 2:38pm | 2409Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. Axcella Health Inc. (NASDAQ: AXLA) shares rose 153% to $0.4105. Axcella Health shares dipped 63% on Friday...
-
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
Friday, December 16, 2022 - 1:39pm | 268Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. The company is spun off of Ligand Pharmaceuticals Inc's (NASDAQ: LGND) antibody discovery business. The analyst says the company is the industry'...
-
Moleculin Biotech's Annamycin In Leukemia Study Shows 80% Overall Response Rate
Thursday, December 15, 2022 - 2:09pm | 232Moleculin Biotech Inc (NASDAQ: MBRX) provided an update on its clinical programs evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The data exhibited an 80% overall response rate (ORR) in the final...
-
Ligand Pharma Issues Mixed Guidance For FY23
Tuesday, December 13, 2022 - 3:47pm | 344At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its OmniAb antibody discovery business. Management also introduced 2023 financial...
-
Luna Innovations Bags Multi-Year Contract From Northrop Grumman
Wednesday, December 7, 2022 - 11:18am | 218Luna Innovations Inc (NASDAQ: LUNA) has extended its existing relationship with Northrop Grumman Corp (NYSE: NOC) by bagging a new multi-year, multi-million-dollar agreement. The agreement includes an initial receipt of an over $3 million incremental, multi-unit purchase order...
-
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth
Wednesday, December 7, 2022 - 9:00am | 284Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS). The primary endpoint was a...
-
Celularity, Moleculin Biotech And 2 Other Penny Stocks Insiders Are Aggressively Buying
Tuesday, November 29, 2022 - 7:11am | 618The Dow Jones closed lower by around 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider...
-
Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling
Monday, November 28, 2022 - 8:40am | 640The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go...
-
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Wednesday, November 23, 2022 - 9:32am | 1984Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. But as exciting as the new treatments and technology coming out of the sector can be, there’s even more experimental biotech that never sees the light of day. Between 2000 and...
-
Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday
Wednesday, November 23, 2022 - 3:48am | 981U.S. stocks closed higher on Tuesday, with the Dow Jones gaining around 400 points. Here is the list of some big stocks recording losses in the previous session. Perfect Corp. (NYSE: PERF) shares tumbled 39.2% to close at $5.27 on Tuesday. Goldman Sachs, on Monday, initiated coverage on Perfect...
-
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Tuesday, November 22, 2022 - 4:49am | 2467Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) jumped 44.5% to close at $1.20. NeuroOne, last month, received...
-
Over $17 Million Bet On Element Solutions? Check Out These 3 Stocks Insiders Are Buying
Wednesday, November 16, 2022 - 9:38am | 492Although US stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider...
-
Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study
Tuesday, November 15, 2022 - 11:00am | 318Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit. The full data comes from the entire 11-week evaluation period, including a 5-week placebo...